NEW YORK, Jan. 11 - Qiagen Sciences has opened its new manufacturing complex in biotech-rich Germantown, Md., the company announced on Friday.
The 200,000-square-foot facility, which becomes Qiagen's new North American headquarters for manufacturing, production, and research and development, will employ 100 R&D personnel and more than 200 manufacturing staff to develop and process DNA separation and purification products.
Manufacturing activities will start by the end of February, the company said. Qiagen is based in Venlo, the Netherlands.
Qiagen generates approximately 60 percent of its consolidated revenues in the United States, said Peer M. Schatz, CFO for Qiagen. The new facility "should have a positive impact on the company's exposure to currency fluctuations, as well as enhance logistics," he added.